PK/PD Modeling and Simulation to understand the disposition and preclinical-to-clinical translation of Antibody Drug Conjugates
April 23, 2014 | Archive Now Available
Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the U.S. Food and Drug Administration (FDA) in 1986. Since then, the pharmaceutical industry has sought opportunities to leverage antibody technology as therapeutic agents to treat human disease. PK/PD modeling has been a useful technique to integrate data generated from diverse test platforms in mechanism framework.
This webinar will focus on :
-Introduction to Antibody Drug Conjugate (ADC)
-Development of mechanistic PK/PD model for preclinical-to-clinical translation of ADCs
-Application of PK/PD modeling to understand the disposition of ADCs and guide the development of ADC
A live Q&A with the audience will follow the presentation.
Dhaval Shah,PhD, MS Pharmaceutics, Assistant Professor, Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York
Dr. Shah worked as a Prinicpal Scientist at Pfizer prior to his current position as Assistant Professor at UB, The State University of New York, his alma mater. Dr. Shah’s research interests include discovery and development of novel biological drugs like ADCs for the treatment of cancer, obesity. His work integrates the principles of PK/PD and mathematical modeling to quantify the efficacy and toxicity of drugs, which in turn provides a predictive systems framework for successful preclinical-to-clinical translation of drugs.
Notable speaking engagements:
A.Bench to Bedside Translation of ADC Efficacy, One Day Workshop at The New York Academy of Sciences held on Tuesday, January 28, 2014
B.Employing PK/PD modeling and simulation to guide ADC development, Presentation at the 2013 World ADC Summit at San-Francisco.
C.Preclinical to Clinical Translation of Antibody Drug Conjugate (ADC) Efficacy using PK/PD Modeling and Simulation, AAPS Webinar on May 9,2013
1.Bench to bedside translation of Antibody Drug Conjugates using a multi scale mechanistic PK/PD model: a case study with brentuximab-vedotin
2.On translation of Antibody Drug Conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
3.Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
|ARCHIVE NOW AVAILABLE
Date : April 23,2014
Managers,Group Head,Laboratory Heads,Scientists,Regulatory Managers,Scientist in the following departments:
- 1.Antibody-Drug Conjugates
9.CMC & Regulatory
Terms and Conditions
Registration provides individual access to the live webinar and/or event recording. If a webinar is postponed due to unforeseen circumstances, the registrant is entitled to attend the rescheduled webinar or to receive a credit for a future webinar
Copyright 2012 Xtalks Ecademy | Part of Honeycomb Worldwide Inc